[CAS NO. 1550371-22-6] BMS-P5freebase

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1550371-22-6]

Catalog

HY-137655A

Brand

MCE

CAS

1550371-22-6

DESCRIPTION [1550371-22-6]

Overview

MDL	-
Molecular Weight	472.58
Molecular Formula	C27H32N6O2
SMILES	O=C(N1[C@@H](C)CC[C@@H](N)C1)C2=CC(OC)=C3C(N=C(C4=CC5=CC=CN=C5N4CC6CC6)N3C)=C2

For research use only. We do not sell to patients.

Summary

BMS-P5 free base is a specific and orally active peptidylarginine deiminase 4 (PAD4) inhibitor. BMS-P5 free base blocks MM-induced NET formation and delays progression of MM in a syngeneic mouse model ^[1] .

In Vitro

BMS-P5 blocks calcium ionophore-induced citrullination of histone H3 ^[1] .
BMS-P5 is also able to inhibit formation of NETs induced by primary MM cells isolated from the BM of patients with MM ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay ^[1] .

Cell Line:	Neutrophils.
Concentration:	10 µM and 100 µM.
Incubation Time:	30 min followed by addition of DP42 or 5TGM1 CM.
Result:	Prevented MM-induced NET formation.

In Vivo

BMS-P5 (50 mg/kg, oral gavage) significantly improves survival of MM-bearing mice ^[1] .
BMS-P5 (50 mg/kg, oral gavage) may attenuate the presence of pro-tumorigenic proteins in the tumor microenvironment, and thus delay tumor progression ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Syngeneic mouse model of MM ^[1] .
Dosage:	50 mg/kg.
Administration:	Oral gavage, twice a day beginning on day 3 after tumor cell injection.
Result:	Significantly delayed development of symptoms and significantly prolonged survival of MM-bearing mice.

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 250 mg/mL ( 529.01 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.1160 mL	10.5802 mL	21.1604 mL
5 mM	0.4232 mL	2.1160 mL	4.2321 mL
10 mM	0.2116 mL	1.0580 mL	2.1160 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.08 mg/mL (4.40 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.08 mg/mL (4.40 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.08 mg/mL (4.40 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Marina Li, et al. A Novel Peptidylarginine Deiminase 4 (PAD4) Inhibitor BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma. Mol Cancer Ther. 2020 Jul;19(7):1530-1538.